newsfilter
← Latest News
Business Wire·

Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders

Remains Opposed to Sale of Acceleron to Merck at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Majo